AMW pioneers the use of artificial intelligence in formulation development
AMW GmbH, a pharmaceutical company specialising in biodegradable implants, has initiated a research and development project aimed at increasing the efficiency of formulation development through the use of AI. The project is being scientifically supported by the research group of Prof. Dr. Olivia Merkel (LMU Munich), an expert in the field of drug delivery. The aim is to analyse large volumes of historical formulation data using machine learning to identify patterns and reduce the number of empirical iteration steps.
Methods such as statistical experimental design (DoE) and a rapid prototyping approach are used to close data gaps. This is based on AMW’s 15 years of research experience with GnRH agonists for the treatment of hormone-dependent tumours. With this data-driven approach, AMW aims to accelerate the development of new formulations and position itself as a pioneer in a previously underserved area of drug development.